AR041024A1 - Derivados de benzimidazol como inhibidores del factor de coagulacion xa - Google Patents

Derivados de benzimidazol como inhibidores del factor de coagulacion xa

Info

Publication number
AR041024A1
AR041024A1 ARP030103008A ARP030103008A AR041024A1 AR 041024 A1 AR041024 A1 AR 041024A1 AR P030103008 A ARP030103008 A AR P030103008A AR P030103008 A ARP030103008 A AR P030103008A AR 041024 A1 AR041024 A1 AR 041024A1
Authority
AR
Argentina
Prior art keywords
hal
coor2
con
atoms
het
Prior art date
Application number
ARP030103008A
Other languages
English (en)
Inventor
Cezanne Bertram Dr
Mederski Werner Dr
Tsaklakidis Christos Dr
Gleitz Johannes Dr
Dorsh Dieter Dr
Barnes Christopher Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR041024A1 publication Critical patent/AR041024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Los nuevos compuestos de la fórmula (1) en la cual D es un anillo carbocíclico o heterocíclico aromático que tiene de 0 a 4 átomos de N, O y/o S, que está insustituido o monosustituido o polisustituido por Hal, A, OR2, N(R2), NO2, CN, COOR2 o CON(R2)2, X y X' son cada uno, en forma independiente entre sí, H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2 o CON(R2)2, R1 es H o A, R2 es H, A, -[C(R1)2]n-Ar', -[C(R1)2]n-Het', -[C(R1)2]n-cicloalquilo, -[C(R1)2n-N(R1)2 o -[C(R1)2]n-OR1, W es _[C(R2)2]nCONR2[C(R2)2]n-, [C(R")2]nNR2CO[C(R2)2]-, [C(R2)2]nO[C(R2)2]-, -[C(R2)2]NNR2[C(R2)2]n-, -[C(R2)2]O[C(R2)2]nCONR2[C(R2)2]n-, -[C(R2)2]nNR2[C(R2)2]n-, -[C(R2)2]nNR2COO[C(R2)2]n- o -[C(R2)2]nS(O)m[C(R2)2]nCONR2[C(R2)2]n-, Y es alqiuleno, cicloalquileno, Het-diilo o Ar-diilo, es un anillo carbocíclico o heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 0 a 4 átomos de N, O y/o S que está insustituido o monosustituido, disustituido o trisustituido por =O, =S, =NR2, =N-CN, =N-NO2, =NOR2, NCOR2, =NCOOR2, NOCOR2, R2,Hal, -[C(R1)2]n- Ar, -[C(R1)2]n-Het, [C(R1)2]n - cicloalquilo, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, COR y/o S(O)mA, A es alquilo no ramificado o ramificado que tiene 1-10 átomos de carbono, en uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o además 1-7 átomos de H pueden estar reemplazados por F, Ar es fenilo, naftilo o bifenilo, cada uno de los cuales está insustituido o monosustituido, disustituido o trisustituido por Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2N(R2)2, S(O)mA, -[(R1)2]n-COOR2 u -O-[C(R1)2]o -COOR2, Ar' es fenilo que está insustituido o monosustituido, disustituido o trisustituido por Hal, A, OR1, N(R1)2, NO2, CN, COOR1, CON(R1)2, NR1COA, NR1SO2A, COR1, SO2N(R1)2, S(O)mA, -[C(R1)2]n, COOR1 u -O-[C(R1)2]o-COOR1, Het es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que está insustituido o monosustituido, disustituido o trisustituido por el oxígeno del carbonilo, =S, =N(R1)2, Hal, A, -[C(R1)2]n-Ar, -[C(R1)2]n-Het', -[C(R1)2]n-cicloalquilo, -[C(R1)2]n-OR2, -[C(R1)2]n-N(R2)2, NO2, CN, -[C(R1)2]n-.COOR2, -[C(R1)2]n-CON(R2)2, -[C(R1)2]nNR2COA, NR2CON(R2)23, -[C(R1)2]n-NR2SO2A, COR2, SO2N(R2)2 y/o S(O)mA, Het' es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que está insustituido o monosustituido o disustituido por el oxígeno del carbonilo, =S, =N(R1)2, Hal, A, OR1, N(R1)2, NO2, CN, COOR1, CON(R1)2, NR1SO2A, COR1, SO2N(R1)2 y/o S(O)mA, Hal es F, Cl, Br o I, m es 0, 1 ó 2, n es 0, 1 ó 2, o es 1, 2 o 3, y derivados, solvatos y estereoisómeros de ellos de uso farmacéutico, incluyendo sus mezclas en todas las proporciones. Son inhibidores del factor de coagulación Xa y pueden emplearse para la profilaxis y/o la terapia de enfermedades tromboembólicas y para el tratamiento de tumores.
ARP030103008A 2002-08-20 2003-08-20 Derivados de benzimidazol como inhibidores del factor de coagulacion xa AR041024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10238002A DE10238002A1 (de) 2002-08-20 2002-08-20 Benzimidazolderivate

Publications (1)

Publication Number Publication Date
AR041024A1 true AR041024A1 (es) 2005-04-27

Family

ID=31197107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103008A AR041024A1 (es) 2002-08-20 2003-08-20 Derivados de benzimidazol como inhibidores del factor de coagulacion xa

Country Status (13)

Country Link
US (1) US7566789B2 (es)
EP (1) EP1558247B1 (es)
JP (1) JP4668614B2 (es)
CN (1) CN1674893A (es)
AR (1) AR041024A1 (es)
AT (1) ATE386518T1 (es)
AU (1) AU2003250890B2 (es)
BR (1) BR0313634A (es)
CA (1) CA2496139C (es)
DE (2) DE10238002A1 (es)
ES (1) ES2303606T3 (es)
RU (1) RU2005108042A (es)
WO (1) WO2004017963A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3000810T (pt) * 2002-03-13 2017-10-25 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
WO2004031145A2 (en) * 2002-10-02 2004-04-15 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
EP1702919B1 (en) * 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
US20060160799A1 (en) 2004-04-23 2006-07-20 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
AU2006295645B2 (en) * 2005-09-30 2011-09-29 Msd K.K. 2-heteroaryl-substituted indole derivative
WO2008076805A2 (en) * 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
US20110166132A1 (en) * 2007-12-13 2011-07-07 Amgen Inc. Gamma Secretase Modulators
MX2010011920A (es) * 2008-05-05 2010-11-26 Amgen Inc Compuestos de urea como moduladores de gamma secretasa.
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
EP2454239B1 (en) 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
MX2012006994A (es) * 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
CA2784765A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
WO2013010904A1 (en) 2011-07-15 2013-01-24 Janssen Pharmaceuticals, Inc. Novel substituted indole derivatives as gamma secretase modulators
WO2013019682A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
ES2608356T3 (es) 2012-12-20 2017-04-10 Janssen Pharmaceutica Nv Novedosos derivados tricíclicos de 3,4-dihidro-2H-pirido[1,2-a]pirazin-1,6-diona como moduladores de la secretasa gamma
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
SG11201702142UA (en) * 2014-10-08 2017-04-27 Redx Pharma Plc N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
IL309666A (en) 2021-07-09 2024-02-01 Plexium Inc Aryl compounds and pharmaceutical preparations that modulate IKZF2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2641060A1 (de) * 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2000071510A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
MXPA01012283A (es) * 1999-06-23 2002-07-30 Aventis Pharma Gmbh Bencimidazoles sustituidos.
ATE290865T1 (de) * 1999-10-19 2005-04-15 Merck & Co Inc Tyrosin kinase inhibitoren
AP1666A (en) * 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate

Also Published As

Publication number Publication date
DE50309217D1 (en) 2008-04-03
AU2003250890B2 (en) 2009-07-16
BR0313634A (pt) 2005-06-21
ATE386518T1 (de) 2008-03-15
US20050272740A1 (en) 2005-12-08
CN1674893A (zh) 2005-09-28
ES2303606T3 (es) 2008-08-16
AU2003250890A1 (en) 2004-03-11
JP2006500369A (ja) 2006-01-05
US7566789B2 (en) 2009-07-28
EP1558247B1 (de) 2008-02-20
CA2496139C (en) 2011-12-13
CA2496139A1 (en) 2004-03-04
WO2004017963A1 (de) 2004-03-04
RU2005108042A (ru) 2005-11-20
DE10238002A1 (de) 2004-03-04
JP4668614B2 (ja) 2011-04-13
EP1558247A1 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
AR041024A1 (es) Derivados de benzimidazol como inhibidores del factor de coagulacion xa
AR043832A1 (es) Compuestos de carbonilo y proceso de preparacion de los mismos
ECSP078003A (es) Inhibidores de aspartil proteasas
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
AR049502A1 (es) Derivados de carbonilo heterociclicos
PE20020337A1 (es) DERIVADOS DE IMIDAZOL COMO INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINA cdk5 Y cdk2
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
UY29246A1 (es) Nuevos compuestos
AR050945A1 (es) Medicamentos que contienen compuestos de carbonilo y su uso
UY27095A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para gaba
AR034870A1 (es) Derivados de 8-metoxi-[1,2,4]triazolo[1,5-a]piridina
AR069244A1 (es) Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
BRPI0014722B8 (pt) compostos inibidores de sglt2, composição farmacêutica e uso dos referidos compostos
AR024242A1 (es) COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO.
AR029805A1 (es) Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento
ES2539790T3 (es) Métodos y composiciones para modular c-met hiperestabilizado
ECSP045253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
GT200000107A (es) Procedimiento para la obtencion de "compuestos de indazol y composiciones farmaceuticas para inhibir las quinasas deproteina y metodos para su uso".
AR030188A1 (es) Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
AR040472A1 (es) Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit
MX9303469A (es) Derivados de benzimidazol, procedimiento para su preparacion, composicion farmaceutica que los contiene y procedimiento para preparar de la misma.
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure